Am J Transplant, Volume 17, Suppl 3 Archives - Page 181 of 181 - ATC Abstracts

2017 American Transplant Congress
A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.
G. de Graav,¹ C. Baan,¹ M. Clahsen-van Groningen,² R. Kraaijeveld,¹ M. Dieterich,¹ W. Verschoor,¹ D. Roelen,³ M. Cadogan,¹ J. van de Wetering,¹ J. van Rosmalen,⁴ W. Weimar,¹ D. Hesselink.¹
¹Internal Medicine, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ²Pathology, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ³Immunohematology and Blood Transfusion, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ⁴Biostatistics, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, has been associated with a higher acute rejection risk than ciclosporin. We sought to identify a biomarker…
2017 American Transplant Congress
Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers.
S. Kilaru,¹ E. Tapper,² M. Curry.³
¹Medicine, NYU School of Medicine, New York, NY; ²Medicine, University of Michigan, Ann Arbor, MI; ³Medicine, Beth Israel Deaconess Medical Center, Boston, MA
Background:Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led…
2017 American Transplant Congress
Knowledge and Attitudes Associated with Willingness to Accept HIV+ Organs Among Persons Living with HIV.
S. Anjum, S. Halpern, K. Kumar, A. Nyugen, S. Rasmussen, A. Massie, A. Tobian, D. Segev, J. Sugarman, C. Durand.
Surgery, Johns Hopkins, Baltimore
HIV-to-HIV organ transplants are a novel treatment for organ failure in HIV-positive (HIV+) individuals. However, attitudes of potential HIV+ recipients regarding HIV+ donors remain unknown.Methods:…
2017 American Transplant Congress
Ectopic Lymphoid Structures Are Present in Type I T-Cell Mediated Kidney Transplant Rejection.
K. de Leur,^1,2 M. Clahsen-van Groningen,³ G. de Graav,¹ D. Hesselink,¹ J. Samsom,⁴ C. Baan,¹ K. Boer.¹
¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands; ²Surgery, Division HPB and Transplant Surgery, Erasmus MC, Rotterdam, Netherlands; ³Pathology, Erasmus MC, Rotterdam, Netherlands; ⁴Pediatrics, Erasmus MC, Rotterdam, Netherlands
BackgroundIn renal transplantation, many allograft recipients develop donor-specific antibodies associated with an increased risk for graft rejection. Current immunosuppressive agents are principally aimed at T-cell-mediated…
2017 American Transplant Congress
Relationship Between Mixed Chimerism and Tolerance in HLA-Matched and -Mismatched Recipients of Kidney and Hematopoietic Cell Transplants.
S. Busque, J. Scandling, J. Shizuru, R. Lowsky, A. Shori, J. Kent, E. Engleman, S. Strober.
Stanford University, Stanford
Twenty-eight fully HLA-matched and 18 HLA haplotype- matched recipients were given combined kidney and hematopoietic cell transplants using a completely post-transplant conditioning regimen consisting of…
2017 American Transplant Congress
A Proof of Concept for Liver Graft Modification Using Warm Ex Vivo Perfusion – “It Is Not Just About Rescuing Marginal Grafts”.
N. Goldaracena, J. Echeverri, N. Selzner, D. Grant, J. Feld, M. Selzner.
Toronto General Hospital, University of Toronto, Toronto, Canada
Background: The active metabolism during normothermic ex vivo liver perfusion (NEVLP) offers a new opportunity to use the preservation time for graft modification and repair…